More important, the data derived from these studies also showed that the activity of this pathway correlates with tumor grade, stage, metastatic potential, relapse after treatment, and reduced patient survival, in patients with tumors harboring activating EGFR, but not KRAS mutations. Here, KRAS is linked to neoplasm.